These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35315510)

  • 1. A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia.
    Chen X; Huang J; Xu N; Fan Z; Nie D; Huang F; Sun Q; Zhang X; Liang X; Shi P; Wang Z; Liu H; Xu J; Dai M; Yu G; Zhang Y; Sun J; Liu Q; Xuan L
    Cancer; 2022 Jun; 128(11):2138-2147. PubMed ID: 35315510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study.
    Wu JJ; Wang WH; Dong M; Ma SS; Zhang XD; Zhu LN; Niu ST; Ding MJ; Zhang JM; Zhang L; Li X; Li L; Sun ZC; Wang XH; Fu XR; Li ZM; Chang Y; Nan FF; Yan JQ; Yu H; Wu XL; Zhou ZY; Zhang MZ
    Invest New Drugs; 2022 Jun; 40(3):650-659. PubMed ID: 35137332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT.
    He JB; Zhang X; Guo ZW; Liu MM; Xu N; Huang F; Fan ZP; Xuan L; Deng L; Lin SH; Xu J; Sun J; Liu QF
    Int J Cancer; 2020 Aug; 147(4):1071-1077. PubMed ID: 31785158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical Characteristics and Prognosis of 21 Cases of Acute Lymphoblastic Leukemia with Central Nervous System Leukemia].
    Jin XS; Yang L; Wang BH; Li HH; Yu L; Jing Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1675-1682. PubMed ID: 28024476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy.
    Khimani NB; Ng AK; Chen YH; Catalano P; Silver B; Mauch PM
    Ann Oncol; 2011 Apr; 22(4):979-984. PubMed ID: 20935059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Value and Prognosis Significance of Cerebrospinal Fluid Examination by Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia.
    Xue L; Shang Q; Lu A; Zuo Y; Ding M; Zhang L; Jia Y
    Technol Cancer Res Treat; 2023; 22():15330338231181025. PubMed ID: 37350078
    [No Abstract]   [Full Text] [Related]  

  • 7. High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis.
    Li Y; Li Y; Zeng R; He Y; Liang L; Ou L; Su C; Zhou H; Xiao L
    J Cancer; 2023; 14(17):3182-3190. PubMed ID: 37928429
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants.
    Wang S; Zhu Y; Qian X; Ding T; Yuan Y; Li Y; Wu H; Chen T
    Adv Clin Exp Med; 2023 Aug; 32(8):855-863. PubMed ID: 36881367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graft-versus-Host Disease Prophylaxis with Post-Transplantation Bendamustine in Patients with Refractory Acute Leukemia: A Dose-Ranging Study.
    Moiseev I; Bondarenko S; Morozova E; Vlasova Y; Dotsenko A; Epifanovskaya O; Babenko E; Botina A; Baykov V; Surkova E; Lapin S; Beynarovich A; Borzenkova E; Golosgchapov O; Kanunnikov M; Kudyasheva O; Ovechkina V; Pirogova O; Porunova V; Rudakova T; Smikova O; Smirnova A; Afansyev B
    Transplant Cell Ther; 2021 Jul; 27(7):601.e1-601.e7. PubMed ID: 33845259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].
    Gu B; Chen GH; Shen HJ; Ma X; Fu CC; Han Y; Tang XW; Miao M; Qiu HY; Sun AN; Wu DP
    Zhonghua Nei Ke Za Zhi; 2016 Apr; 55(4):293-7. PubMed ID: 27030618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance of serum and cerebrospinal fluid MMP-9, CCL2 and sVCAM-1 in leukemia CNS metastasis.
    Si MY; Fan ZC; Li YZ; Chang XL; Xie QD; Jiao XY
    J Neurooncol; 2015 Apr; 122(2):229-44. PubMed ID: 25630624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of osteopontin in central nervous system leukemia and its clinical significance].
    Fang XM; Pan XH; Chen M; Zeng WW; Li Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):325-8. PubMed ID: 23628025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies.
    Mustafa O; Abdalla K; AlAzmi AA; Elimam N; Abrar MB; Jastaniah W
    J Oncol Pharm Pract; 2019 Dec; 25(8):1831-1838. PubMed ID: 30518307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity as the initial manifestation of central nervous system relapse of acute lymphoblastic leukemia: case report and literature review.
    Zhang LD; Li YH; Ke ZY; Huang LB; Luo XQ
    J Cancer Res Ther; 2012; 8(1):151-3. PubMed ID: 22531539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial.
    Dietrich J; Versmee L; Drappatz J; Eichler AF; Nayak L; Norden A; Wong E; Pisapia MR; Jones SS; Gordon AB; Chabner BA; Hochberg F; Batchelor TT
    Oncologist; 2020 Sep; 25(9):747-e1273. PubMed ID: 32520407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive role of cerebrospinal fluid hydrogen sulfide in central nervous system leukemia.
    DU SX; Xiao J; Guan F; Sun LM; Wu WS; Tang H; DU JB; Tang CS; Jin HF
    Chin Med J (Engl); 2011 Nov; 124(21):3450-4. PubMed ID: 22340157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
    Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
    Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
    [No Abstract]   [Full Text] [Related]  

  • 19. Decitabine prior to salvaged unrelated cord blood transplantation for refractory or relapsed childhood acute leukemia.
    Zhou H; Zheng C; Zhu X; Tang B; Tong J; Zhang X; Zhang L; Liu H; Sun Z
    Pediatr Transplant; 2016 Dec; 20(8):1117-1124. PubMed ID: 27620713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of CNSL at diagnosis of childhood B-cell acute lymphoblastic leukemia: A report from the South China Children's Leukemia Group.
    Xu LH; Geng X; Liao N; Yang LH; Mai HR; Wan WQ; Huang LB; Zheng MC; Tian C; Chen HQ; Chen QW; Long XJ; Zhen ZJ; Liu RY; Li QR; Wu BY; Wang LN; Kong XL; Chen GH; Fang JP; Li Y
    Front Oncol; 2022; 12():943761. PubMed ID: 36033509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.